Nikolay Dimolarov

Nikolay Dimolarov has extensive experience in various roles within the technology and healthcare industries. Nikolay is currently the Founder & CTO of Kranus Health, a global provider of Prescription Digital Therapeutics. In this role, they have successfully developed and launched the CE-certified product "Kranus Edera," the first fully reimbursable therapy for erectile dysfunction, supported by a large clinical trial.

Prior to their current role, Dimolarov served as a Senior Product Manager at Celonis, where they played a crucial role in scaling out the company globally, overseeing platform infrastructure and data lake teams. Nikolay also worked as a Tech Executive for Software Engineering at Motius and gained experience in IT strategy and financial services compliance at KPMG Deutschland.

Dimolarov has a solid background in software development, having worked as a Software Developer at Siemens and Payoneer. Additionally, they co-founded a brand called Orchids and Eons, specializing in premium handcrafted leather goods and accessories, where they were responsible for web development, eCommerce, UI/UX, branding, and social media.

Nikolay has also contributed to the tech community as a Contributing Writer for Towards Data Science and is a member of alphalist and The WE Network.

Overall, Nikolay Dimolarov's work experience showcases their diverse skill set and their ability to drive innovation and success in various industries.

Nikolay Dimolarov's education history includes a Master of Science (M.Sc.) degree in Media Informatics from Ludwig-Maximilians-Universität München. Nikolay also obtained an International Baccalaureate from Schule Schloss Salem. In addition to their formal education, Nikolay has obtained several certifications in various fields. These include a CORe Certificate Program (Business Administration) from Harvard Business School in 2020, Data Scientist Training from Celonis in October 2019, and multiple certificates in machine learning and deep learning from Coursera in 2018 and 2017.